中
繁
EN
Search form
Search this site
For Patients
Investors
Careers
Contact
Home
About Us
Our Story
Leadership
Board of Directors
Jacobio people stories
Platform & Pipeline
Platform
Pipeline
Publications
Partnership
News
Company News
Media Report
Company News
97
press releases in total
Year
-Year
2026
2025
2024
2023
2022
2021
2020
2019
2018
2026
Aug 3, 2026
A One-two Punch: An EGFR-directed ADC With a KRAS Inhibitor Payload
Jul 27, 2026
Jacobio Doses First Patient in China in Phase IIa Clinical Trial of BET Inhibitor JAB-8263 for Rheumatoid Arthritis
[More]
Jul 21, 2026
Jacobio's BET Inhibitor JAB-8263 for Myelofibrosis Included in CDE Rare Disease Innovative Drug Development Pilot Program
[More]
Jul 20, 2026
Jacobio Announces First Patient Dosed in China in Phase Ib/III Trial of JAB-23E73 in Combination with Chemotherapy for First-Line Treatment of KRAS-Mutant Pancreatic Cancer
[More]
Jul 10, 2026
Jacobio Pharma’s Associate Company Jacoray Receives IND Clearance in China for JAR-2203 Injection
[More]
Jul 6, 2026
Jacobio Investee GenEditBio Receives NMPA IND Clearance for Lead Genome-Editing Program
[More]
Jun 25, 2026
Jacobio’s Invested Company HebeCell Received FDA IND Clearance for Its Cell Therapy Program
[More]
Jun 18, 2026
Jacobio Pharma Engages Pharmaron to Initiate Manufacturing of JAB-23E73 for Registrational Clinical Trials
[More]
May 15, 2026
Jacobio Pharma’s BET Inhibitor JAB-8263 Approved for Phase IIa Clinical Trial in Rheumatoid Arthritis in China
[More]
May 13, 2026
Jacobio Pharma Appoints Dr. Yan Chen as Vice President of CMC to Accelerate Development of Its Small Molecule and xADC Platforms
[More]
May 11, 2026
Jacobio-Licensed KRAS G12C and SHP2 Inhibitor Combination Receives Breakthrough Therapy Designation in China
[More]
Mar 30, 2026
Jacobio Pharma Receives US$100 Million Upfront Payment from AstraZeneca
[More]
Mar 11, 2026
Jacobio Announces 2025 Annual Results
[More]
2025
Dec 21, 2025
Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73
[More]
Dec 5, 2025
Glecirasib Colorectal Cancer Data Published in The Lancet Gastroenterology & Hepatology
[More]
Dec 1, 2025
Jacobio’s KRAS G12C and SHP2 Combination Therapy Published in The Lancet Respiratory Medicine
[More]
Nov 13, 2025
Jacobio Pharma Announces Establishment of Co-CEO System
[More]
Nov 11, 2025
Jacobio Included in the MSCI China All Shares Small Cap Index
[More]
Oct 24, 2025
Jacobio Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International Conference
[More]
Oct 15, 2025
Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline
[More]
Pages
1
2
3
4
5
›
»
京公网安备 11030102011242号